The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02792218




Registration number
NCT02792218
Ethics application status
Date submitted
2/06/2016
Date registered
7/06/2016
Date last updated
1/07/2020

Titles & IDs
Public title
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Scientific title
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Secondary ID [1] 0 0
2015-005418-31
Secondary ID [2] 0 0
COMB157G2301
Universal Trial Number (UTN)
Trial acronym
ASCLEPIOS I
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ofatumumab subcutaneous injection
Treatment: Drugs - Placebo orally matching to teriflunomide
Treatment: Drugs - Teriflunomide orally
Treatment: Drugs - Placebo subcutanous injection matching to ofatumumab

Experimental: Ofatumumab - Syringes for subcutaneous injection
Patients will also take a placebo capsules (matching in appearance to teriflunomide)

Active Comparator: Teriflunomide - Oral capsule
Patients will also take subcutaneous injections of placebo (syringes matching in appearance to ofatumumab)


Treatment: Drugs: Ofatumumab subcutaneous injection
Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks

Treatment: Drugs: Placebo orally matching to teriflunomide
Placebo orally, matching in appearance to teriflunomide, administered once daily

Treatment: Drugs: Teriflunomide orally
Patients randomized to the teriflunomide arm will take teriflunomide orally once daily

Treatment: Drugs: Placebo subcutanous injection matching to ofatumumab
Placebo-containing syringes, matching in appearance to syringes containing ofatumumab, administered every 4 weeks

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized relapse rate (ARR) - ARR is the number of confirmed relapses in a year calculated based on cumulative number of relapses by patient adjusted for time-in-study by patient
Timepoint [1] 0 0
up to 2.5 years
Secondary outcome [1] 0 0
Time to 3-month confirmed disability worsening on EDSS - A 3-month confirmed disability worsening is an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at last 3 months.
Timepoint [1] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [2] 0 0
Time to 6-month confirmed disability worsening on EDSS - A 6-month confirmed disability worsening is an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at last 6 months.
Timepoint [2] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [3] 0 0
Time to 6-month confirmed disability improvement on EDSS - A 6-month confirmed disability improvement is a decrease from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months.
Timepoint [3] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [4] 0 0
Number of gadolinium (Gd)-enhancing lesions per MRI scan - Total number of Gd-enhancing lesions across all scans per patient adjusted for different number of scans due to variable follow up time in study
Timepoint [4] 0 0
Baseline, yearly up to 2.5 years
Secondary outcome [5] 0 0
Number of new or enlarging T2 lesions on MRI per year (annualized lesion rate) - Number of new/enlarging T2 lesions on last available MRI scan compared to baseline adjusted for different time of scans versus baseline due to variable follow up time in study
Timepoint [5] 0 0
Baseline, yearly up to 2.5 years
Secondary outcome [6] 0 0
Neurofilament light chain (NfL) concentration in serum - The NfL concentration (geometric mean concentration) will be estimated by treatment and time point with using a repeated measures model on the basis of all evaluable log-transformed NfL values.
Timepoint [6] 0 0
Baseline, every 3 months up to 2.5 years
Secondary outcome [7] 0 0
Rate of brain volume loss based on assessments of percentage brain volume change from baseline - Percent change from baseline in brain volume loss (BVL) on all MRI scans adjusted for different time of scan versus baseline due to variable follow up time in study
Timepoint [7] 0 0
Baseline, yearly up to 2.5 years

Eligibility
Key inclusion criteria
- Diagnosis of multiple sclerosis (MS)

- Relapsing MS (RRMS or SPMS) course

- At least 1 relapse during the previous 1 year or 2 relapses during the previous 2
years or a positive gadolinium-enhancing MRI scan in previous year

- EDSS score of 0 to 5.5
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Primary progressive MS

- Disease duration of more than 10 years in patients with an EDSS score of 2 or less

- Patients with an active chronic disease of the immune system other than MS

- Patients at risk of developing or having reactivation of hepatitis

- Patients with active systemic infections or with neurological findings consistent with
PML

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Novartis Investigative Site - New Lambton Heights
Recruitment hospital [2] 0 0
Novartis Investigative Site - St Leonards
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fe
Country [27] 0 0
Argentina
State/province [27] 0 0
Cordoba
Country [28] 0 0
Belgium
State/province [28] 0 0
Brasschaat
Country [29] 0 0
Belgium
State/province [29] 0 0
Brugge
Country [30] 0 0
Belgium
State/province [30] 0 0
Liege
Country [31] 0 0
Belgium
State/province [31] 0 0
Pelt
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Plovdiv
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Sofia
Country [34] 0 0
Canada
State/province [34] 0 0
British Columbia
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Croatia
State/province [36] 0 0
HRV
Country [37] 0 0
Croatia
State/province [37] 0 0
Zagreb
Country [38] 0 0
Czechia
State/province [38] 0 0
Czech Republic
Country [39] 0 0
Czechia
State/province [39] 0 0
CZE
Country [40] 0 0
Czechia
State/province [40] 0 0
JIhlava
Country [41] 0 0
Czechia
State/province [41] 0 0
Pardubice
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 5
Country [43] 0 0
Denmark
State/province [43] 0 0
Aarhus
Country [44] 0 0
Denmark
State/province [44] 0 0
Copenhagen
Country [45] 0 0
Denmark
State/province [45] 0 0
Odense C
Country [46] 0 0
Estonia
State/province [46] 0 0
Tallinn
Country [47] 0 0
Estonia
State/province [47] 0 0
Tartu
Country [48] 0 0
France
State/province [48] 0 0
Cedex
Country [49] 0 0
France
State/province [49] 0 0
Lille Cedex
Country [50] 0 0
France
State/province [50] 0 0
Nantes Cedex 1
Country [51] 0 0
France
State/province [51] 0 0
Nimes Cedex
Country [52] 0 0
France
State/province [52] 0 0
Toulouse Cedex 9
Country [53] 0 0
Germany
State/province [53] 0 0
Aschaffenburg
Country [54] 0 0
Germany
State/province [54] 0 0
Barsinghausen
Country [55] 0 0
Germany
State/province [55] 0 0
Bayreuth
Country [56] 0 0
Germany
State/province [56] 0 0
Berg
Country [57] 0 0
Germany
State/province [57] 0 0
Bielefeld
Country [58] 0 0
Germany
State/province [58] 0 0
Duesseldorf
Country [59] 0 0
Germany
State/province [59] 0 0
Hamburg
Country [60] 0 0
Germany
State/province [60] 0 0
Marburg
Country [61] 0 0
Germany
State/province [61] 0 0
Muenchen
Country [62] 0 0
Germany
State/province [62] 0 0
Neuburg an der Donau
Country [63] 0 0
Germany
State/province [63] 0 0
Potsdam
Country [64] 0 0
Germany
State/province [64] 0 0
Ulm
Country [65] 0 0
Germany
State/province [65] 0 0
Wiesbaden
Country [66] 0 0
Greece
State/province [66] 0 0
GR
Country [67] 0 0
Greece
State/province [67] 0 0
Athens
Country [68] 0 0
Greece
State/province [68] 0 0
Thessaloniki
Country [69] 0 0
Hungary
State/province [69] 0 0
HUN
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Kistarcsa
Country [72] 0 0
Hungary
State/province [72] 0 0
Szeged
Country [73] 0 0
India
State/province [73] 0 0
Delhi
Country [74] 0 0
India
State/province [74] 0 0
Karnataka
Country [75] 0 0
India
State/province [75] 0 0
Kerala
Country [76] 0 0
India
State/province [76] 0 0
Maharashtra
Country [77] 0 0
India
State/province [77] 0 0
Punjab
Country [78] 0 0
India
State/province [78] 0 0
West Bengal
Country [79] 0 0
India
State/province [79] 0 0
Mangalore
Country [80] 0 0
India
State/province [80] 0 0
New Delhi
Country [81] 0 0
Israel
State/province [81] 0 0
Ashkelon
Country [82] 0 0
Israel
State/province [82] 0 0
Haifa
Country [83] 0 0
Israel
State/province [83] 0 0
Sefad
Country [84] 0 0
Israel
State/province [84] 0 0
Tel Aviv
Country [85] 0 0
Italy
State/province [85] 0 0
MI
Country [86] 0 0
Italy
State/province [86] 0 0
PA
Country [87] 0 0
Italy
State/province [87] 0 0
RM
Country [88] 0 0
Italy
State/province [88] 0 0
VA
Country [89] 0 0
Italy
State/province [89] 0 0
Napoli
Country [90] 0 0
Mexico
State/province [90] 0 0
Distrito Federal
Country [91] 0 0
Mexico
State/province [91] 0 0
Jalisco
Country [92] 0 0
Netherlands
State/province [92] 0 0
BG
Country [93] 0 0
Netherlands
State/province [93] 0 0
Amsterdam
Country [94] 0 0
Netherlands
State/province [94] 0 0
Rotterdam
Country [95] 0 0
Poland
State/province [95] 0 0
Bydgoszcz
Country [96] 0 0
Poland
State/province [96] 0 0
Gdansk
Country [97] 0 0
Poland
State/province [97] 0 0
Katowice
Country [98] 0 0
Poland
State/province [98] 0 0
Kielce
Country [99] 0 0
Poland
State/province [99] 0 0
Lodz
Country [100] 0 0
Puerto Rico
State/province [100] 0 0
Guaynabo
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Kemerovo
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Moscow
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Nizhny Novgorod
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Novosibirsk
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Saint Petersburg
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Saransk
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Sestroretsk
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Tyumen
Country [109] 0 0
Slovakia
State/province [109] 0 0
Banska Bystrica
Country [110] 0 0
Slovakia
State/province [110] 0 0
Bratislava
Country [111] 0 0
Slovakia
State/province [111] 0 0
Nitra
Country [112] 0 0
Slovakia
State/province [112] 0 0
Trnava
Country [113] 0 0
Spain
State/province [113] 0 0
Andalucia
Country [114] 0 0
Spain
State/province [114] 0 0
Cataluna
Country [115] 0 0
Spain
State/province [115] 0 0
Catalunya
Country [116] 0 0
Spain
State/province [116] 0 0
Cataluña
Country [117] 0 0
Spain
State/province [117] 0 0
Murcia
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Valencia
Country [120] 0 0
Sweden
State/province [120] 0 0
Goeteborg
Country [121] 0 0
Sweden
State/province [121] 0 0
Stockholm
Country [122] 0 0
Switzerland
State/province [122] 0 0
Basel
Country [123] 0 0
Thailand
State/province [123] 0 0
THA
Country [124] 0 0
Turkey
State/province [124] 0 0
Istanbul
Country [125] 0 0
Turkey
State/province [125] 0 0
Izmir
Country [126] 0 0
Turkey
State/province [126] 0 0
Kocaeli
Country [127] 0 0
Turkey
State/province [127] 0 0
Samsun
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Oxfordshire
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Glasgow
Country [130] 0 0
United Kingdom
State/province [130] 0 0
London
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Stoke-on-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4
weeks versus teriflunomide administered orally once daily in patients with relapsing multiple
sclerosis
Trial website
https://clinicaltrials.gov/show/NCT02792218
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications